−0.16CNY
−75.85 MCNY
2.12 BCNY
202.61 M
About ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD
Sector
Industry
CEO
Wei Yi Shen
Website
Headquarters
Taizhou
Employees (FY)
1.84 K
Founded
1997
ISIN
CNE1000026N8
FIGI
BBG006FTGD55
Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. Its products include fluorine quinoline derivatives, carbapenem, iohexol, ioversol, iopamidol, iopromide, iodixanol, levofloxacin, levofloxacin hydrochloride, levofloxacin acid ester, levofloxacin acid, pazufloxacin, pazufloxacin mesylate, meropenem, faropenem sodium, iomeprol, and gadobenate dimeglumine. The company was founded on September 15, 1997 and is headquartered in Taizhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 603520 is 11.43 CNY — it has decreased by 0.26% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD stocks are traded under the ticker 603520.
ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD is going to release the next earnings report on Apr 19, 2024. Keep track of upcoming events with our Earnings Calendar.
603520 stock is 3.50% volatile and has beta coefficient of 1.41. Check out the list of the most volatile stocks — is ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD there?
603520 earnings for the last quarter are −0.05 CNY per share, whereas the estimation was −0.93 CNY resulting in a 94.60% surprise. The estimated earnings for the next quarter are −0.93 CNY per share. See more details about ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD earnings.
ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD revenue for the last quarter amounts to 425.09 M CNY despite the estimated figure of 56.61 M CNY. In the next quarter revenue is expected to reach 119.27 M CNY.
Yes, you can track ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD financials in yearly and quarterly reports right on TradingView.
603520 stock has fallen by 0.78% compared to the previous week, the month change is a 10.14% fall, over the last year ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD has showed a 34.23% decrease.
603520 net income for the last quarter is 4.04 M CNY, while the quarter before that showed 25.71 M CNY of net income which accounts for −84.28% change. Track more ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD financial stats to get the full picture.
Today ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD has the market capitalization of 3.93 B, it has increased by 1.84% over the last week.
Yes, 603520 dividends are paid annually. The last dividend per share was 0.20 CNY. As of today, Dividend Yield (TTM)% is 1.75%. Tracking ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD dividends might help you take more informed decisions.
Like other stocks, 603520 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 1.84 K employees. See our rating of the largest employees — is ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD stock shows the sell signal. See more of ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.